Drug
Efimosfermin Alfa
Efimosfermin Alfa: highest development phase Phase 3, developed by GlaxoSmithKline. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efimosfermin alfa NCT07704892 | Phase 3 | Metabolic Dysfunction-associated Steatohepatitis |
| Efimosfermin alfa NCT07701993 | Phase 3 | Metabolic Dysfunction-associated Steatohepatitis |
| Efimosfermin alfa NCT07358546 | Phase 1 | Non-alcoholic Fatty Liver Disease |
Latest
No recent events.
Follow Efimosfermin Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.